Clinical study design

Results: 811



#Item
351RECOMBINANT DNA ADVISORY COMMITTEE Minutes of Meeting March 14, 2007 U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES Public Health Service

RECOMBINANT DNA ADVISORY COMMITTEE Minutes of Meeting March 14, 2007 U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES Public Health Service

Add to Reading List

Source URL: osp.od.nih.gov

Language: English - Date: 2013-12-10 09:47:37
352Clinical Trial Research News From the Office of Clinical Research Volume 9, Issue 4  July / August 2007

Clinical Trial Research News From the Office of Clinical Research Volume 9, Issue 4 July / August 2007

Add to Reading List

Source URL: www.sbrc.ca

Language: English - Date: 2011-09-07 18:51:21
353U.S. Food and Drug Administration  Notice: Archived Document The content in this document is provided on the FDA’s website for reference purposes only. This content has not been altered or updated since it was archived

U.S. Food and Drug Administration Notice: Archived Document The content in this document is provided on the FDA’s website for reference purposes only. This content has not been altered or updated since it was archived

Add to Reading List

Source URL: www.fda.gov

Language: English
354Barbara Riley, PhD, Propel Centre, University of Waterloo Marjorie MacDonald, PhD, University of Victoria Building Synergies, January 20-22, 2010, Hamilton, ON Learning Objectives By the end of this session, participant

Barbara Riley, PhD, Propel Centre, University of Waterloo Marjorie MacDonald, PhD, University of Victoria Building Synergies, January 20-22, 2010, Hamilton, ON Learning Objectives By the end of this session, participant

Add to Reading List

Source URL: strengthenphc.mcmaster.ca

Language: English - Date: 2012-11-21 13:43:42
355HB 615: Cancer Clinical Trials Draft Study Report Monica J. Lindeen, Commissioner of Securities and Insurance, Montana State Auditor March 2, 2012 A. INTRODUCTION With the passage of HB 615, the 2011 Legislature directed

HB 615: Cancer Clinical Trials Draft Study Report Monica J. Lindeen, Commissioner of Securities and Insurance, Montana State Auditor March 2, 2012 A. INTRODUCTION With the passage of HB 615, the 2011 Legislature directed

Add to Reading List

Source URL: www.csi.mt.gov

Language: English - Date: 2012-03-13 15:11:51
356

PDF Document

Add to Reading List

Source URL: www.fda.gov

Language: English
357Subgroup analyses of adverse events by age, sex, race and prior BOTOX@ treatment showed no statistically significant differences between the treatment groups. Reviewer’s Comments and Conclusions on studies: Clinical Tr

Subgroup analyses of adverse events by age, sex, race and prior BOTOX@ treatment showed no statistically significant differences between the treatment groups. Reviewer’s Comments and Conclusions on studies: Clinical Tr

Add to Reading List

Source URL: www.fda.gov

Language: English
358US Food and Drug Administration Pulmonary-Allergy Drugs Advisory Committee Meeting February 23, 2012 Susan Limb, MD Clinical Team Leader

US Food and Drug Administration Pulmonary-Allergy Drugs Advisory Committee Meeting February 23, 2012 Susan Limb, MD Clinical Team Leader

Add to Reading List

Source URL: www.fda.gov

Language: English
359Applied ethics / Criminal law / Medical ethics / Design of experiments / Pharmacology / Institutional review board / Human subject research / Prison / Parole / Ethics / Clinical research / Research

INDIANA UNIVERSITY EAST INSTITUTIONAL REVIEW BOARD (IRB) REVIEW REQUEST FORM FOR THE INCLUSION OF PRISONERS IN RESEARCH Principal Investigator: IRB Study:

Add to Reading List

Source URL: www.iue.edu

Language: English - Date: 2010-04-28 08:58:04
360Impetus Data Analysis Clinical Trial Simulations Conclusions  Trial Design, Endpoints for

Impetus Data Analysis Clinical Trial Simulations Conclusions Trial Design, Endpoints for

Add to Reading List

Source URL: www.accp1.org

Language: English - Date: 2011-03-25 17:37:15